Background
==========

Since the discovery of human immunodeficiency virus (HIV) as the causative agent in 1983, the HIV-1 pandemic is characterized by an extensive variability and the circulation of numerous genotypes and recombinant forms (CRFs) \[[@B1],[@B2]\]. Subtype C is the most prevalent, estimated to represent 48% infections in the HIV-1 pandemic \[[@B3]\]. Subtype C is predominant particularly in south and east Africa \[[@B4]\]. This strongly contrasts with the situation in central Africa where a marked genetic heterogeneity is observed.

HIV-1 remains a crucial global health problem. Delivery of ART in low and middle income countries has required utilization of a public health approach in which standardized, rather than individualized, regimens are prescribed to very large numbers of HIV-1-infected individuals \[[@B5]\]. At present, the majority of individuals in these countries are initiating first-line therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTI) \[[@B6]\].

The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. Nevertheless, patients in routine clinical care experience sustain detectable viral replication even under potent combination therapy. Various factors underlie this failure to achieve viral suppression, but resistance to current medications has been increasingly recognized as an important factor. Rational choice of the NRTI component of second-line therapy should be based on patterns of resistance developed during first-line therapy \[[@B7]\].

Djibouti is the smallest country in east Africa. The estimated prevalence of HIV-1 infection was around 2.5% (2009). Since the introduction of antiretroviral therapy in 2004, no data exist on the epidemiology of drug resistance mutations and little was known about HIV-1 genotypes circulating in Djibouti. Data on drug resistance in the routine care setting are urgently required to check ART efficacy. The present study aims to characterize circulating HIV-1 subtypes and to identify drug resistance mutations in patients who first-line therapy failed (\>1000 copies/mL) and antiretroviral-naive patients from Djibouti.

Materials and methods
=====================

Population study and sample collection
--------------------------------------

Between October and December 2009, the whole blood samples were collected in Djibouti city from 35 HIV-1 infected patients consulting at three health centers (Hôpital General Peltier, N = 23, Centre Yonis Thoussaint, N = 9 and Centre Paul Faure, N = 3). EDTA (ethylenediaminetetraacetic acid-anticoagulated) plasma specimens were obtained after centrifugation, and stored at −80°C in aliquots for later assessment of HIV RNA viral-load and genotypic drug resistance testing. The ethical aspects of this study were approved by the local committee. For all participants, blood collection was performed after informed consent, under the supervision of local sanitary authorities.

Viral load and CD4
------------------

The CD3/CD4+ cells were enumerated by flowcytometry (BD FACSCount System) and the quantification of HIV-1 viral load (VL) was measured using NASBA, NucliSENS®EasyQ Assays (BioMerieux) at the central laboratory of "Hôpital General Peltier" in Djibouti.

The plasma samples were shipped to the Laboratory of Microbiology of "Charles Nicolle" Hospital (Tunis, Tunisia) for drug resistance genotyping tests.

Drug resistance genotyping
--------------------------

For Drug Resistance genotyping, the viral RNA was isolated from plasma samples using DSP virus RNA kit (QIAGEN Inc.) and reverse transcribed to make complementary DNA (cDNA) copies using a cDNA synthesis kit the One Step RT-PCR (QIAGEN Inc). The reverse transcriptase (RT) and protease (PR) genes were amplified according to the ANRS consensus sets of primers: for the RT gene amplification, MJ3 and MJ4 primers were used for a first PCR (RT-PCR), and A(35) with NE1(35) as inner primers for nested PCR. For the protease gene amplification, 5′Prot1 and 3′Prot1 outer primers were used and the 5′Prot2 and 3′Prot2 as inner primers: (ANRS: <http://www.hivfrenchresistance.org/ANRS-procedures.pdf>).

RT-PCR involved a reverse transcription step at 50°C for 30 minutes, followed by 95°C for 15 minutes before proceeding to 40 cycles of 95°C for 45 seconds, 50°C for 30 seconds and 72°C for 1 minute 30 seconds, with a final extension step of 10 minutes at 72°C. The RT-PCR products were then subjected to nested PCR with the following cycling conditions: a denaturation step of 2 minutes at 95°C, and then 35 cycles with 1 cycle consisting of 30 seconds at 95°C, 30 seconds at 55°C and 30 seconds at 72°C with a final extension at 72°C for 7 minutes.

PCR products (5 μL) were resolved by electrophoresis on a 1.5% agarose gel *GellyPhorLE, (Euroclone, UK)*. DNA bands were stained with *RedSafe™ Nucleid Acid Staining Solution \[20,000*~*X*~*\] (iNtRON Biotechnology, Inc, Korea)*. They were then visualized in UV light to assess the presence of fragments of the expected length compared with the standard marker *SharpMass™50-DNA ladder (Euroclone, Wetherby, UK)*. The amplification products were purified using QIAquick PCR Purification kit (QIAGEN Inc).

The PCR products were finally sequenced on an ABI3130 Genetic Analyser (Applied Biosystems), and compared with HXB-2 sequence using SeqScape v2.6 software (Life technologies). All sequences were subjected to quality assessment and determination of DR mutation profile (susceptible, intermediate resistance and resistance) using the Stanford Database (available at <http://hivdb.stanford.edu/>).

Results
=======

This study includes 35 HIV-1-infected Djiboutian patients enrolled between October and December 2009. Their mean age was 32.3 years. Among these patients, nineteen patients were ART-naïve (54.2%) and 16 were first-line ART failures (45.8%). In ART naïve patients, the median CD4 count was 144 cells/μl and the average viral load was 5.58 log10/ml (388 643 copies/ml). For the patients with first-line ART failure, the median CD4 count was 178 cells/μl, viral loads mean was 5.62 log10/ml and the median time of therapy was 30 months (Table  [1](#T1){ref-type="table"}). There were 20 females (57%) which were not pregnant at the time of blood collection. Genetic subtyping revealed that 65.7% of samples were infected with subtype C, 20% with CRF02_AG, 8.5% with B, 2.9% with CRF02_AG/C and 2.9% with K/C (Table  [2](#T2){ref-type="table"}).

###### 

Patients characteristics

                                 **ART-naïve patients**   **Patients with first-line ART failure**
  ----------------------------- ------------------------ ------------------------------------------
  Effectives                               19                                16
  Age (Mean, Years)                        32                              32.67
  CD4 (cells/μl) Mean                     144                               178
  CVp (log 10 copies/ml) Mean             5.58                              5.62

###### 

HIV-1 subtypes and distribution of resistance-associated mutations among 19 ART-naïve patients attending three health centers in Djibouti city between October and December 2009

  **Patients**    **SEX**   **CD4**   **VL (cp/mL)**  **SUBTYPE**    **NRTI**  **NNRTI**       **Major Mutation PI**   **Minor Mutation PI**
  -------------- --------- --------- ---------------- ------------- ---------- -------------- ----------------------- -----------------------
  1                  M        208        170 000      C                None    None                    None                    None
  2                  M        107       4 690 000     C                None    None                    None                    None
  3                  F        186       1 600 000     CRFO2_AG         None    K103N                   None                    None
  4                  M        167        150 000      C                None    None                    None                    None
  5                  F        195        160 000      C                None    None                    None                    None
  6                  F        154         98 000      C                None    None                    None                    None
  7                  F        104         3 360       CRF02_AG         None    None                    None                    None
  8                  F        47         350 000      C                None    K101Q, K103N            None                    None
  9                  M        126         76 000      CRFO2_AG         None    None                    None                    L10V
  10                 M        100        150 000      C                None    None                    None                    None
  11                 M        20         420 000      CRF02_AG         None    None                    None                    None
  12                 F        51          45 000      K/C              None    None                    None                    None
  13                 F        540        260 000      C                None    None                    None                    None
  14                 M        56          43 900      C                None    None                    None                    None
  15                 F        23         663 000      C                None    None                    None                    None
  16                 M        49         185 000      C                None    None                    None                    None
  17                 F        170         87 200      B                None    K101E                   None                    None
  18                 F        250        120 000      C                None    None                    None                    None
  19                 F        90         431 000      C                None    None                    None                    None

The ART naïve patients showed only NNRTI-associated mutations which were K103N (2 strains) and K101Q (1). No mutations of NRTI were detected. The minor PI mutation L10V was detected in one ART naïve patient \[[@B8]\].

At the time of sampling, all the patients receiving ART were treated by first line. According to the Djiboutian National Program for fighting against AIDS (PNLS) recommendations \[[@B9]\], the first-line treatment consists in 2 NRTI + 1NNRTI. The NRTI backbones were stavudine, zidovudine, and lamivudine. The most used drug combination (12 Patients (75%)) was AZT/3TC/EFV, while the 6 other patients received either AZT/3TC/NVP, D4T/3TC/EFV or D4T/3TC/NVP. The NRTI-associated mutations were D67N (2 strains), T69N (1), M184V (6), L210W (2), T215Y (2). The NNRTI-associated mutations were K101Q (1), K103N (4), V179E (1), Y181C (1), Y188L (2), G190A (2) (Table  [3](#T3){ref-type="table"}). For PI-associated mutations, the minor mutation L10V and other polymorphism were detected.

###### 

HIV-1 subtypes and distribution of resistance-associated mutations among 16 patients with first-line ART failure attending three health centers in Djibouti city between October and December 2009

  **N°**    **SEX**   **CD4**  **SUBTYPE**    **VL (cp/mL)**   **TREATMENT**  **NRTI**                                **NNRTI**                     **Major Mutation PI**   **Minor Mutation PI**
  -------- --------- --------- ------------- ---------------- --------------- --------------------------------------- ---------------------------- ----------------------- -----------------------
  20           F        62     C                 630 000        AZT/3TC/EFV   None                                    None                                  None                    None
  21           M        92     C                 220 000        AZT/3TC/EFV   None                                    None                                  None                    None
  22           F        346    C                  1 900         AZT/3TC/EFV   None                                    None                                  None                    None
  23           M        176    C                  21 000        AZT/3TC/EFV   None                                    None                                  None                    None
  24           F        220    C                   3270         AZT/3TC/EFV   None                                    None                                  None                    None
  25           F        243    C                  7 500         AZT/3TC/EFV   None                                    None                                  None                    None
  26           F        103    C                 413 000        D4T/3TC/NVP   None                                    K101Q, Y181C                          None                    None
  27           M        52     C                  26 000        AZT/3TC/EFV   M184V                                   K103N                                 None                    None
  28           M        249    C                 213 000        D4T/3TC/EFV   D67N, M184V, L210W, T215Y               Y188L, G190A                          None                    None
  29           F        230    C                1 080 000       AZT/3TC/EFV   M41L, D67N, L74V, M184V, L210W, T215Y   K103N, G190A, H221Y, M230L            None                    None
  30           F        140    CRFO2_AG          168 000        D4T/3TC/EFV   None                                    None                                  None                    None
  31           F        250    CRF02_AG/C         72 720        AZT/3TC/NVP   K70KR, M184V, K219R                     K103N                                 None                    None
  32           M        92     CRFO2_AG           21 000        AZT/3TC/EFV   T69N                                    V179E, Y188L                          None                    L10V
  33           M        88     CRFO2_AG           7 100         AZT/3TC/EFV   M184V                                   K103N                                 None                    L10V
  34           F        208    B                  1 300         D4T/3TC/NVP   A62V                                    None                                  None                    None
  35           M        105    B                4 837 560       AZT/3TC/EFV   A62V, M184V, T215F, K219Q               None                                  None                    None

Drug susceptibility results were classified into three categories: susceptible, intermediate resistance and resistance. Of the 16 patients with first-line ART failure, 56.25% showed resistance to at least one antiretroviral molecule: two patients (12.5%) were resistant to nucleoside (NRTI), one (6.25%) to non-nucleoside (NNRTI) reverse transcriptase inhibitors, and six (37.5%) to both. We found that the resistance rates to Lamivudine and Nevirapine in the 16 patients with first-line ART failure were 37.5% and 43.75% respectively. Forty four percent (44%) of sequences from viral strains did not show any mutation associated to ARV drug resistance- 7out of 16 \[[@B10]\]. Therefore, therapeutic solutions using second line drugs could be proposed to our patients with therapeutic failure and drug resistance mutations.

Discussion
==========

Minimizing drug resistance to highly active antiretroviral therapy (HAART) is important. First, it maximizes the opportunity for successful second-line and subsequent therapies after viral rebound during first-line treatment; second, it limits the transmission of drug-resistant viruses. We report results of the HIV-1 genetic diversity and prevalence of mutations associated with antiretroviral drugs among ART naïve as well as patients who failed first line therapy. The HAART was introduced in Djibouti in 2004. Djibouti, surrounded by Eritrea, Ethiopia, and Somalia, is an important crossroad for trade and exchange.

Our result revealed a majority of subtype C (\~66%). In fact, Subtype C prevalence has been described in the Horn of Africa \[[@B11]-[@B14]\] and a similar prevalence was previously reported in Djibouti in 2005 \[[@B15],[@B16]\]. However, our study describes the subtype B in Djibouti for the first time. It is the predominant subtype in the Western world and the clade that has circulated in North America and Europe. The detection of CRF02_AG strains indicates that they are still circulating in Djibouti, the only country in East Africa in which this recombinant virus was found some years ago \[[@B17],[@B18]\]. CRF02_AG recombinant isolates were primarily described in West and Central Africa \[[@B19],[@B20]\]. The discordances observed between RT and PR sequences in 2 isolates (CRF02_AG/C, K/C) are probably attributable to the high variability of the genome of HIV in particularly intra subtype recombination within group M subtype C \[[@B21]\].

For the ART naïve patients, the low rate of CD4 and the high rate of VL can be explain by the fact that 80% of patients infected by HIV in Djibouti was already detected at an advanced stage of the epidemic according to WHO classification \[[@B22],[@B23]\]. Among the 19 strains, 2 were resistant only to non-nucleoside reverse transcriptase inhibitors (NNRTIs) while one strain showed a minor mutation to PI. Detection of RT and protease mutations associated with drug resistance in individuals who have not been exposed to antiretroviral therapy is thought to result from either transmission from a treated individual.

Concerning first-line ART failures, 38% of 16 strains sequenced in this group had the M184V mutation. This mutation is selected by lamivudine (3TC), emtricitabine (FTC) or abacavir (ABC) use and confers high-level resistance to 3TC (Figure  [1](#F1){ref-type="fig"}) \[[@B24]\]. Patients receiving incompletely suppressive 3TC regimens usually develop M184V as their first mutation \[[@B25],[@B26]\]. Accumulation of the other mutations observed included thymidine associated mutations (including M41L, D67N, K70R, L210W, T215Y/F, K219Q) results in increasing resistance to AZT, Tenofovir, D4T, Abacavir, and DDI \[[@B27],[@B28]\]. Two multidrug resistance mutation profiles in general, confer high level drug resistance to all NRTIs. The most common occurring nucleotide excision mutations (NEMs) that confer resistance by enhanced excision \[[@B29]\] were at position 215. The T215Y mutation was observed in 13% of the sequences while T215F was detected in 6%. Clinical studies have shown that the NEMs, particularly mutations at position 215, interfere with the clinical response to zidovudine, stavudine, abacavir, didanosine, and most dual NRTI combinations \[[@B30]\]*.* Mutations conferring resistance to NNRTIs were also seen, with one strain showing resistance only to NNRTIs. The NNRTI resistance-conferring mutations included K103N (25%), Y188L (12.5%), Y181C (6%), G190A (6%), H221Y (6%), M230L (6%). Our data suggest the non-epidemic circulation of resistant viruses, and the absence of multi-class drug resistant viral strains.

![**Frequencies of resistance levels to nucleoside (NRTI) and non-nucleoside (NNRTI) reverse transcriptase inhibitors.** The horizontal bars indicates the frequency of susceptible (white), intermediate resistance (grey) and resistant (black) samples to NRTI and NNRTI reverse transcriptase inhibitors.](1746-1596-7-138-1){#F1}

It is important to appreciate that resistance at failure is only one factor to consider when choosing an initial HAART regimen. Coformulation, simplicity of administration, price, drug interactions (particularly with tuberculosis therapy), toxicity and adverse events are all important considerations and will differ between patient populations. We noticed seven patients (\~44%) did not show resistance-conferring mutations and the therapeutic failure may have been due to other factors \[[@B31]-[@B35]\]. Information on treatment from their clinic folders allowed us to confirm that for five of these seven cases the ART failure profile was due to poor adherence and for the remaining two cases the detectable viral level was due to coinfection with tuberculosis and malnutrition \[[@B36]-[@B38]\].

The escalating rates of transmission of drug resistant virus observed in the past few years, coupled with the poorer response to treatment in persons with drug resistant virus, are being considered as a basis for a recommendation that resistance tests should be performed routinely for persons with new HIV infection \[[@B39]\]. This evaluation, both at the baseline and in follow-up, will be crucial to assess the impact of therapy regimens on resistance development and also their adequation.

Conclusion
==========

This study reveals primary mutations that confer resistance to NRTI, NNRTI in HIV-1 non-B and B subtype strains, isolated from ART naïve as well as patients who failed first line therapy in Djibouti. It also illustrates the importance of preliminary surveys of drug-resistance mutations in resource-poor countries. Therefore, we suggest the use of resistance testing to check the prevalence of the drug resistance mutation that arises following failure of the first line regimen. This will help in establishing guidelines for second line regimens in Djibouti. This allows the selection of adapted antiretroviral regimens in these regions. Our results provide a basis for repeated epidemiological studies to measure the population effects of HIV treatment programs over time.
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